Soligenix Inc., formerly known as DOR BioPharma Inc., a late-stage biotechnology company, today announced it has formed a consortium to develop technology to enhance acting vaccines, including RiVax, the company’s proprietary vaccine for ricin toxin, which can be used as a biological weapon. Soligenix also announced it was awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to continue this work.

The announced consortium draws together industry and academic researchers from various disciplines, including the University of Colorado, the University of Kansas, and the Tulane National Primate Research Center, SRI International, Health Research Inc, Battelle Memorial Institute, Nanotherapeutics, and BioCon Inc.

“Each of our academic and industry consortium members brings impressive expertise to our vaccine stabilization program,” Dr. Robert N. Brey, PhD, chief scientific officer of Soligenix stated in the press release. “This association has the potential

...

Emtec Federal is a wholly-owned subsidiary of Emtec Inc., an information technology (IT) solutions provider. Emtec Federal announced today that its Springfield, New Jersey headquarters received ISO 9001: 2008 certification demonstrating its focus on quality management.

ISO 9000 is a family of standards for quality management systems, maintained by the International Organization for Standardization (ISO). The rules are continuously updated and were last changed on November 15, 2008, creating the current ISO 9001: 2008 standard. The ISO certification process ensures on-going compliance to standards of performance, and, once certified, companies are externally audited on a regular basis for continuous adherence to the standards.

Organizations that receive the ISO 9001: 2008 certification must offer a quality management system that demonstrates the ability to consistently provide products and services that meet customer and applicable statutory and regulatory requirements. In addition, these organizations must also enhance customer satisfaction through the effective application of the system,

...

Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling

...

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for HIV/AIDS (HIV-1, Human Immunodeficiency Virus), today told the investment community of partial success in the recently completed Phase 3 trial in Thailand of a candidate HIV/AIDS vaccine. According to the press release, this completed study represents the first HIV/AIDS vaccine trial to show prevention of infection.

Robert McNally, Ph.D., Chief Executive Officer and President stated, “The results are highly encouraging for the clinical studies of our HIV/AIDS vaccine and we congratulate the Thai ministry of Public Health for successful conduct of a groundbreaking trial that included 16,000 volunteers and was supported by multiple agencies including the U.S. Army and the U.S. National Institutes of Health (NIH).”

“The partial success of this trial is very important to the GeoVax vaccine, because the vaccine tested in Thailand, like the GeoVax vaccine, was designed to elicit both T cells and antibody,” commented Dr. Harriet

...

DOR BioPharma Inc. is a late-stage biotechnology company that has been gaining national attention for its state-of-the-art technology. DOR reached a major milestone in the advancement of its company with the announcement that it has been awarded a $9.4 million grant from the National Institute of Allergy and Infectious Diseases, which is a division of the National Institute of Health (NIH).

This grant will assist the company’s future over the next five years with the development of formulation and manufacturing processes for vaccines, including RiVax(TM), that are stable at elevated temperatures. The grant will also fund the development of improved thermostable adjuvants expected to result in rapidly acting vaccines that can be given with fewer injections over shorter intervals.

The development of heat-stable vaccines will take advantage of combining several novel formulation processes with well-characterized adjuvants that have been evaluated in numerous vaccine field trials. The formulation and process technology funded

...

Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.

Moreover, there will be huge profit opportunities, in many enabling technologies, for those who invest accordingly. And today I’m going to tell you about a company that will hand you your best chance to make a transformational fortune.

We know that many current treatments work on some people, yet not others. Some drugs are safe for many people, but have dangerous side effects for others. This is because all of us have individual differences in our genetic code based on heredity and environment. Even slight differences can lead to very different reactions to medications.

This has created serious regulatory problems. Drugs are denied regulatory approval not because they do not work, but because some

...

Provectus Pharmaceuticals Inc. is quickly gaining a reputation as an up-and-coming development-stage oncology and dermatology biopharmaceutical company. Helping to enhance this reputation and its position in the marketplace, Provectus announced the addition of Mount Sinai School of Medicine as the second and final site for its expanded Phase 2 clinical trial of the company’s lead dermatology agent PH-10 for psoriasis. Jason Elmer, M.D., who served as the lead investigator for the Phase 2 clinical trial of PH-10 for atopic dermatitis of which patent enrollment was completed in June, will also serve as the principal investigator of this trial.

Commenting on the value of Dr. Elmer’s work on this project, Provectus CEO Craig Dees, Ph.D. stated, “Dr. Emer’s work with PH-10 for atopic dermatitis, his involvement in the ongoing research of the product as a dermatological therapy, and Mount Sinai School of Medicine’s outstanding reputation in dermatological research make this

...

DrStockPick.com Stock Report!

Tuesday August 18, 2009

**************************************************************

Aruba Networks, Inc. (NASDAQ: ARUN), a global leader in wireless LANs and secure mobility solutions, today announced that it is the first wireless LAN vendor to have its 802.11n solution and ArubaOS Release 3 validated within the FIPS 140-2 Federal Information Processing Standard for cryptographic security. The validation encompasses Aruba’s 200, 800, 3000 and 6000 Series Multi-Service Mobility Controllers, 802.11a/b/g/n indoor and outdoor access points, resilient mesh software, and Remote Access Point (RAP) technology. Leveraging field-proven hardware platforms and software applications allows Aruba to deliver a rich feature set with predictable performance, avoiding the throughput bottlenecks, degraded reliability, management issues, and added expense

...

OriginOil Inc. (OTCBB: OOIL) receives updated Speculative Buy from Beacon Analyst Victor Sula, Ph.D., fueled by the Company’s recent patent applications for its “milking” process to extract algae oil, a patent filing for its Dynamic Control System, and its application or a Patent Cooperation Treaty for low-energy, high-efficiency algae production.

Solar Energy Initiatives, Inc. (OTCBB:SNRY), executing on a grass roots campaign, “RENEW THE NATION,” to help redeploy a portion of the U.S. workforce and focus on reducing the world’s dependence on fossil fuels by selling solar thermal and photovoltaic (PV) technologies, today announced that it has secured federal stimulus funding to train displaced workers as solar energy installation and maintenance technicians.

PolyMedix, Inc. (OTC BB: PYMX, www.polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, and the University of Massachusetts at Amherst, Department of Polymer Sciences and Engineering, announced today that they have received

...

Luminex Corp. (LMNX) posted revenue of $104.5 million in 2008, marking growth of 39% from 2007. Technology segment sales increased 34% to $83.6 million, while Assay segment sales grew 66% to $20.9 million. Through the first quarter 2009, Technology segment sales grew 13% to $21.1 million and Assay segment sales increased 2% to $4.5 million. Total revenue grew 11% in the first quarter to $25.6 million. Technology segment sales continue to be driven by growth in consumables and royalties.

EPS came in at $0.08 in 2008 and $0.04 (adjusted for litigation expense) in the first quarter 2009, compared to ($0.47) and ($0.03) in the year-earlier periods, respectively. Gross margins increased by 240 basis points in the most recent quarter as the company's product mix shifted towards higher margin consumables and royalties.

At the first quarter earnings release, management reduced 2009 revenue guidance to between $125 million and $135

...